The page is the record's research on the issuer — no analyst, no rating, no view.

Genmab A/S (DK0010272202) — research page

DK · dk-cm-kg/XCSE/DK0010272202 · as of 2026-11-06

Identity and listing

The issuer is Genmab A/S, listed on Nasdaq Copenhagen under ticker DK0010272202, with ISIN DK0010272202 and LEI 529900MTJPDPE4MHJ122. Security type, segment, sector and jurisdiction are not on the record. Listing status is listed, not halted.

fieldvaluesource · read date
nameGenmab A/Ssource · 2026-11-06
exchangeNasdaq Copenhagensource · 2026-11-06
tickerDK0010272202source · 2026-11-06
ISINDK0010272202source · 2026-11-06
LEI529900MTJPDPE4MHJ122source · 2026-11-09
security typenot on the record
segmentnot on the record
sectornot on the record
jurisdictionnot on the record
statuslisted, not haltedsource · 2026-11-09

The disclosure read

The record holds 91 filings on 74 filing days in the window 2025-11-06 to 2026-11-06. The median gap between filing days is 3 days, and the median latency from the latest filing to the record date is 1 day. Nasdaq Copenhagen has 119 issuers with a median cadence gap of 8.0 days, a median of 25 filings and a median latency of 4.0 days. Sector peer figures are not on record for this market. The latest filing is an Interim report (Q1 and Q3) dated 2026-11-05.

filingsmedian gap between filing daysdays from latest filing to as-of
this issuer9131
exchange median: Nasdaq Copenhagen (119 issuers)2584
datetypecategoryfiling
2026-11-05Interim report (Q1 and Q3)Interim report (Q1 and Q3)Genmab Announces Financial Results for the Nine Months of 2026
2026-11-04Investor NewsInvestor NewsGenmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
2026-10-28Inside informationInside informationGenmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer
2026-10-26Investor NewsInvestor NewsGenmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2026-10-25Investor NewsInvestor NewsGenmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them

Auditor

The auditor of record and its location are not on the record. Auditor changes are not on the record, as this register has no lifecycle type map yet.

Events and halts

Listing, delisting, name change, domicile change and segment move are not on the record, as this register has no lifecycle type map yet. The issuer is listed and not halted.

Orderability

The outcome is not determinable under rule version acm-68000/dk/mifid-ii-product-governance/r1, because the chapter's orderability section, as of 2026-11-04, carries no client categories.

rule acm-68000/dk/mifid-ii-product-governance/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability

Coverage

No research houses were found on the issuer's investor-relations pages read.

Open research

No openly published research notes were found on the record.

Licensed

Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.

licensorentitlementtitledatesource
none loaded

As-of depth

The market's vintage is not sealed, and no issuer years are sealed. The market's earliest sealed date is not on the record, and the live record began date is not on the record.

Sources

6 source pages are named on this page; every value above carries its own source page and read date in the numbers.

10.1
https://firds.esma.europa.eu/firds/ (identity.exchange)
10.2
https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)
10.3
https://mcp.dk-cm-kg.ai/events/XCSE/DK0010272202 (the disclosure lines)
10.4
https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=exchangeNewsFilterCPH|FirstNorthInformationCPH (the halt flag)
10.5
https://dk.eu-cm-kg.ai/book/aio.json (the orderability chapter)
10.6
https://mcp.dk-cm-kg.ai/record/XCSE/DK0010272202 (the record)

Read it by agent

The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"DK0010272202"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:02d22a9b9c91602f.